Thought Leadership
 
Email Page
Status Quo Maintained: FDA Reverses Course on Generic Product Labeling
March 1, 2019
Chad Landmon and Eric Dunbar
FDLI Update

Axinn partner Chad Landmon and associate Eric Dunbar* authored the FDLI’s Update article, "Status Quo Maintained: FDA Reverses Course on Generic Product Labeling." Click here to access the article.

*At the time of this writing, Eric Dunbar's admission to the New York bar is pending. Shared with the permission of FDLI.